Influence of emphysema distribution on pulmonary function parameters in COPD patients by Bastos, Hélder Novais et al.
ISSN 1806-3713© 2015 Sociedade Brasileira de Pneumologia e Tisiologia
http://dx.doi.org/10.1590/S1806-37562015000000136
ABSTRACT
Objective: To evaluate the impact that the distribution of emphysema has on clinical and 
functional severity in patients with COPD. Methods: The distribution of the emphysema 
was analyzed in COPD patients, who were classified according to a 5-point visual 
classification system of lung CT findings. We assessed the influence of emphysema 
distribution type on the clinical and functional presentation of COPD. We also evaluated 
hypoxemia after the six-minute walk test (6MWT) and determined the six-minute walk 
distance (6MWD). Results: Eighty-six patients were included. The mean age was 65.2 ± 
12.2 years, 91.9% were male, and all but one were smokers (mean smoking history, 62.7 
± 38.4 pack-years). The emphysema distribution was categorized as obviously upper 
lung-predominant (type 1), in 36.0% of the patients; slightly upper lung-predominant 
(type 2), in 25.6%; homogeneous between the upper and lower lung (type 3), in 16.3%; 
and slightly lower lung-predominant (type 4), in 22.1%. Type 2 emphysema distribution 
was associated with lower FEV1, FVC, FEV1/FVC ratio, and DLCO. In comparison with 
the type 1 patients, the type 4 patients were more likely to have an FEV1 < 65% of the 
predicted value (OR = 6.91, 95% CI: 1.43-33.45; p = 0.016), a 6MWD < 350 m (OR = 
6.36, 95% CI: 1.26-32.18; p = 0.025), and post-6MWT hypoxemia (OR = 32.66, 95% 
CI: 3.26-326.84; p = 0.003). The type 3 patients had a higher RV/TLC ratio, although 
the difference was not significant. Conclusions: The severity of COPD appears to be 
greater in type 4 patients, and type 3 patients tend to have greater hyperinflation. The 
distribution of emphysema could have a major impact on functional parameters and 
should be considered in the evaluation of COPD patients.
Keywords: Pulmonary disease, chronic obstructive; Pulmonary emphysema; Respiratory 
function tests; Tomography, X-ray computed.
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INTRODUCTION 
The lung disease known as COPD is characterized by 
persistent airflow limitation that is usually progressive, 
consisting of a combination of small airways disease 
(obstructive bronchiolitis) and parenchymal destruction 
(emphysema).(1) There is increasing evidence to suggest 
that distinguishing different phenotypic profiles of patients 
with COPD has prognostic and therapeutic implications.(2-4) 
In fact, COPD patients with confirmed emphysema have 
more severe lung function impairment, more intense airway 
inflammation, and possibly more important extrapulmonary 
disability than do those without emphysema.(2,5,6) The 
lung hyperinflation caused by the loss of lung elastic recoil 
has been associated with limitations in the functional 
capacity of these patients. (7,8) In addition, the destruction 
of the alveolar-capillary membrane in emphysema is 
responsible for more profound hypoxemia.(9)
Advances in CT scanning and image processing software 
have allowed the precise measurement of the extent of 
low-attenuation areas corresponding to emphysema. In 
validation studies, the results obtained with these tech-
niques have been found to correlate well with pathologic 
and functional features.(10-13) This kind of assessment 
has been mainly used in order to evaluate patients 
for lung volume reduction procedures and to monitor 
replacement therapy in alpha-1 antitrypsin-deficient 
patients.(14-16) However, quantifying emphysema might 
have broader utility, given that some reports have shown 
that the heterogeneity of the distribution of parenchymal 
damage might be associated with different degrees of 
clinical severity.(13,17-19) Nevertheless, the results are 
contradictory, which might be attributable to the different 
methods that have been used in those analyses. The 
majority of authors have employed computer-assisted 
measurements, which are expensive and not widely 
available. In order to promote a definitive widespread 
use of imaging data in the clinical evaluation of patients 
with emphysema, we believe that there is also a need 
to standardize qualitative methods.
The aim of the present study was to evaluate the impact 
that the distribution of emphysema has on clinical and 
functional features in COPD patients. In order to test 
our hypothesis, we used a visual classification system to 
categorize patients according to the regional distribution 
of their emphysema.
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METHODS
Study subjects
This was a cross-sectional observational study 
involving COPD patients with emphysema, recruited 
between August of 2011 and August of 2012 from the 
pulmonology outpatient clinic of the Centro Hospitalar 
de São João, a tertiary care medical center located in 
the city of Porto, Portugal. We included patients with 
pulmonary emphysema and any degree of airflow 
limitation who had been clinically stable in the 3 months 
prior to their inclusion in the study. The inclusion 
criteria were having a post-bronchodilator FEV1/FVC 
< 0.70 and showing evidence of emphysema on visual 
inspection of CT images, estimated to involve > 25% 
of the lung parenchyma.(20) Patients with a history of 
asthma, bronchiectasis, tuberculosis sequelae, lung 
fibrosis, thoracic surgery, or other confounding diseases 
were excluded (Figure 1). The study was approved by 
the local research ethics committee, and all patients 
gave written informed consent.
Clinical and pulmonary function assessment
We recorded demographic and anthropometric data, 
namely age, gender, and BMI.(21) Patients also underwent 
clinical evaluation, which included the completion of the 
COPD Assessment Test (CAT) and the modified Medical 
Research Council (mMRC) scale (for the determination 
of dyspnea severity),(22) as well as the evaluation of 
smoking status (current smoker, former smoker, or 
nonsmoker), smoking history (in pack-years), the 
presence of significant comorbidities, and current 
medication use. The number of COPD exacerbations in 
the last year(23,24) was retrospectively obtained by patient 
recall, and, in most cases, hospital records were used 
in order to corroborate the information. Each patient 
was submitted to spirometry (MasterScreen™ Body; 
Jaeger, Würzburg, Germany), lung volumes and DLCO 
also being determined, in accordance with international 
guidelines.(25,26) The six-minute walk test (6MWT) was 
performed using the methodology described by the 
American Thoracic Society.(27) Arterial blood gases 
were measured (RapidLab™ 1265; Siemens, Munich, 
Germany) after a minimum 30-min rest period in a 
sitting position. We defined hypoxemia as a PaO2 < 
60 mmHg at an FiO2 of 0.21.
CT evaluation
All patients underwent multidetector CT of the chest 
at suspended full inspiration, from the thoracic inlet to 
the adrenal glands, using a 64-detector row scanner 
(Somatom Sensation 64; Siemens Healthcare, Erlangen, 
Germany). The following imaging parameters were 
used: tube voltage, 120 kVp; tube current, 40 mAs; 
rotation time, 0.33 s; pitch, 1.3; detector collimation, 
32 × 0.6 mm; and slice acquisition by means of a 
z-flying focal spot, 64 × 0.6 mm. No contrast media 
were used. From the raw data, 1 mm-thick sections 
were obtained using a soft tissue kernel reconstruction 
(B50f; Siemens Healthcare). For the subjects submitted 
to multiple CT scans, the one performed the closest 
to study enrollment was used.
Two thoracic radiologists independently reviewed the 
CT imaging studies. Both were blinded to the clinical 
information of the patients. Disagreement between 
the two radiologists was resolved by consensus. 
They reviewed CT images on the coronal and sagittal 
planes to assess the heterogeneity of emphysematous 
changes in an apical-to-caudal direction. For image 
interpretation, we used a window level of −700 to 
−900 HU and a window width of 600-1,600 HU.(28) A 
five-point visual classification system was applied, as 
previously described.(18) This qualitative evaluation ranks 
pulmonary emphysema according to its predominant 
distribution, as follows: type 1, obviously predominant 
in the upper lung; type 2, somewhat predominant 
in the upper lung; type 3, equal extent in the upper 
and lower lung (homogeneous distribution); type 4, 
somewhat predominant in the lower lung; and type 
5, obviously predominant in the lower lung.
Statistical analysis
Variables with normal distribution are expressed as 
means and standard deviations, whereas those with 
non-normal distribution are expressed as median 
and interquartile range (25th to 75th percentile) and 
categorical variables are expressed as absolute values 
and proportion. The Student’s t-test for independent 
samples was used in order to compare variables with 
normal distribution, and the Mann-Whitney U rank test 
was used in order to compare variables with non-normal 
distribution. The Pearson’s chi-square test was used 
for categorical variables. One-way ANOVA was used in 
order to compare the emphysema distribution groups, 
together with Tukey’s post hoc test to identify significant 
differences. Odds ratios and the corresponding 95% 
confidence intervals were calculated using binary logistic 
regression. Odds ratios were adjusted for age and BMI. 
Statistical significance was set at p < 0.05 (two-tailed), 
and all statistical analyses were performed with the 
SPSS Statistics software package, version 19.0 (IBM 
Corporation, Armonk, NY, USA). 
118 COPD patients with pulmonary emphysema
16 without significant
emphysema or with missing data
102
86
16 with bronchiectasis, fibrosis,
lobectomy, or other predominant
lung parenchymal disease
Figure 1. Flowchart for the selection of the participating 
patients.
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RESULTS
During the study period, 86 COPD patients with 
pulmonary emphysema were selected, the character-
istics of whom are shown in Table 1. Male gender was 
predominant in this population, all but one of the patients 
were current or former smokers, and 1 patient presented 
with homozygous PiZZ alpha-1 antitrypsin deficiency. 
The CAT scores indicated severe symptoms more often 
than did the mMRC dyspnea scale scores: 56.1% of the 
patients had CAT scores ≥ 10, whereas only 40.8% had 
mMRC scale scores ≥ 2. Only 24.4% of the patients had 
frequent exacerbations (≥ 2 exacerbations in the last 
year). Hypoxemia was present in 15 patients (18.8%). 
The characteristics of the patients demonstrated a wide 
range of airflow limitation, with an even distribution 
across the Global Initiative for Chronic Obstructive 
Lung Disease severity classification,(1) which is based 
on FEV1—mild, in 27.9%; moderate, in 22.1%; severe, 
in 29.1%; and very severe, in 20.9%—reflecting the 
spectrum of the disease encountered in clinical practice. 
However, there was a clear tendency for hyperinflation 
to be seen in this group of patients, with a median 
residual volume/total lung capacity (RV/TLC) ratio of 
55.5% and a significant median oxygen desaturation 
during the 6MWT of 6%.
In most (36.0%) of the patients, the emphysema 
was obviously predominant in the upper lung (type 1 
distribution). The next most common distributions were 
types 2 and 4 (somewhat predominant in the upper lung 
and somewhat predominant in the lower lung, seen in 
25.6% and 22.1% of the patients, respectively). Type 
3 emphysema distribution (homogeneous distribution 
between the upper and lower lung) was the least 
common, seen in only 16.3%. None of the patients in 
our sample were classified as presenting with type 5 
emphysema distribution (obviously predominant in the 
lower lung). The interobserver correlation for emphysema 
classification scores was good (rs = 0.621, p < 0.001).
Figure 2 shows the differences found in the clinical 
parameters according to CT scan classification of 
emphysema distribution. The six-minute walk distance 
(6MWD), post-6MWT oxygen desaturation, FVC, FEV1, 
and FEV1/FVC ratio (in % of the predicted values), as 
well as DLCO, were found to differ significantly among 
the groups. Tukey’s post hoc test revealed that there 
were significant differences in all of the abovementioned 
variables between the patients classified as type 1 
than those classified as type 4. In fact, all of those 
variables appear to get worse in upper-to-lower 
predominance direction. Patients classified as type 3 
showed the highest RV/TLC ratio, although it did not 
reach statistical significance (p = 0.064).
The logistic regression analysis for different 
dimensions of the functional status revealed that type 
4 patients had a significantly higher risk for having 
Table 1. Demographic, clinical, and imaging characteristics of selected patients with emphysema-predominant COPD.a
Characteristic (n = 86)
Age,years 65.2 ± 12.2
Gender
Male 79 (91.9)
Female 7 (8.1)
BMI, kg/m
2
23.1 ± 4.5
Smoking history, pack-years 54 (38-79)
mMRC dyspnea scale score 1 (0.5-3.0)
mMRC dyspnea scale score ≥ 2 35 (40.8)
CAT score 12 (7.0-22.5)
CAT score ≥ 10 48 (56.1)
Exacerbations in the last year 1 (0-2)
≥ 2 exacerbations in the last year 21 (24.4)
Hypoxemia 15 (18.8)
Post-6MWT desaturation, % 6 (4.0-9.8)
6MWD, m 400 (256.3-463.8)
FVC, % of predicted
FEV1
FEV1/FVC ratio
RV
TLC
RV/TLC ratio
DLCO
86.1 ± 24.8
50.0 (32.0-83.3)
45.9 (35.0-63.2)
162.0 (125.1-225.0)
118.3 ± 24.4
55.5 (43.9-67.1)
59.0 (40.0-77.7)
Emphysema distribution
Type 1 (obvious upper-lung predominance)
Type 2 (slight upper-lung predominance)
Type 3 (equal upper- and lower-lung extent)
Type 4 (slight lower-lung predominance)
31 (36.0)
22 (25.6)
14 (16.3)
19 (22.1)
mMRC: modified Medical Research Council; CAT: COPD Assessment Test; 6MWT: six-minute walk test; and 6MWD: 
six-minute walk distance. aValues are presented as mean ± SD, n (%), or median (interquartile range).
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FEV1 < 65% of the predicted value (adjusted OR = 
6.92; 95% CI: 1.43-33.45; p = 0.016), 6MWD < 350 
m (adjusted OR = 6.36; 95% CI: 1.26-32.18; p = 
0.025), and hypoxemia (adjusted OR = 32.66; 95% 
CI: 3.26-326.84; p = 0.003; Table 2). However, none 
of the different types of emphysema distribution were 
found to be significant predictors of BMI ≤ 21 kg/m2, ≥ 
2 exacerbations in the last year, mMRC dyspnea scale 
score ≥ 2, or post-6MWT oxygen desaturation ≥ 4%.
DISCUSSION
Although COPD is a highly heterogeneous disease, 
its phenotyping can be more precise when CT of the 
lung parenchyma is combined with an evaluation of 
the clinical and physiological characteristics. Here, 
we describe the role of using a qualitative analysis of 
CT findings in order to determine the distribution of 
pulmonary emphysema and the potential contribution 
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Figure 2. Lung functional characteristics of patients with different emphysema distribution. *Indicates a p value < 0.05. 
6MWT: six-minute walk test; type 1: obviously predominant emphysema in upper lung; type 2: somewhat predominant 
emphysema in upper lung; type 3: equal extent of emphysema in upper and lower lung; and type 4: somewhat 
predominant emphysema in lower lung.
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of that distribution to further characterizing the clinical 
severity of these patients.
Patients with COPD were classified according to a 
subjective heterogeneity analysis of upper versus lower 
lung distribution of pulmonary emphysema, using a 
visual scoring system first described by Chae et al.(18) 
In their assessments of the regional heterogeneity of 
the distribution of emphysema, those authors found 
a significant correlation between the quantitative 
assessment (with a computer algorithm) and the 
visual assessment. They also found that there was 
a considerable interobserver agreement in the visual 
assessment. Therefore, visual assessment of the 
distribution of pulmonary emphysema could be a 
reliable method, with one major advantage, which is 
the fact that everyone can use it, especially when CT 
analysis software is not available.
Our results suggest that, among COPD patients 
with emphysema, there is greater COPD severity, 
defined as a higher degree of airflow obstruction and 
lower alveolar-capillary diffusing capacity, in those 
with predominantly lower-lung emphysema, whereas 
functional status is better in those with predominantly 
upper-lung emphysema. These results can be explained, 
in part, by the smaller area of the lung affected when 
emphysema is predominantly in the upper lobes. 
Regarding the COPD patients with homogeneous 
emphysema (type 3), our data indicate a tendency 
toward higher hyperinflation, with a higher RV/TLC 
ratio (Figure 2), although the difference did not reach 
statistical significance. That is probably associated with 
the broader, more uniform distribution of parenchymal 
destruction, together with the fact had a median pack-
year smoking history was higher among the patients 
with type 3 emphysema distribution (60 pack-years 
vs. 40.5 pack-years for those with type 1 emphysema 
distribution; p = 0.012). 
After stratifying the study population according to 
the cut-off values for the assignment of at least 1 
point on the Body mass index, airflow Obstruction, 
Dyspnea, and Exercise capacity (BODE) index,(21) 
which assesses the risk of death for COPD patients, we 
observed that type 4 emphysema distribution (slightly 
predominant in the lower lung) significantly increases 
the risk of severe airway obstruction (FEV1 < 65% of 
predicted) and reduced the 6MWD to < 350 m (Table 
2). Hypoxemia was identified as another risk factor for 
mortality in COPD.(21,29) Our results show that patients 
with emphysema that is slightly predominant in the 
lower lung are more likely to be hypoxemic.
Our findings are consistent with those of previous 
studies showing a strong association between lower-zone 
emphysema and airflow limitation.(18,19,30) In another 
study, however, upper-zone predominance of emphy-
sema was associated with a worse total St George’s 
Respiratory Questionnaire score, although it was not 
significantly associate with FEV1 (% of predicted).
(17) 
Reports are also inconsistent concerning the relationship 
between diffusing capacity and regional differences in 
emphysema distribution. Gurney et al.(31) observed 
that DLCO is more strongly affected by lower-lung 
emphysema than by upper-lung emphysema, whereas 
Parr et al.(32) found DLCO to be relatively preserved in 
patients with lower-lung emphysema. Those differences 
might be attributable to the different methods applied 
for assessing the regional distribution of emphysema. 
The present study has a number of limitations. First, 
the female gender is not well represented in this study 
group. However, that is representative of the gender 
distribution of emphysema patients treated at our 
outpatient clinic. Second, our sample did not include 
any subjects with clearly lower lung-predominant 
emphysema (type 5). Because most of the patients 
were smokers, that type of emphysema distribution 
(sparing the upper lung) would be expected to be rather 
rare. We can presume that the clinical-radiological 
correlations for type 5 emphysema would be similar 
to those found for type 4. In order to extrapolate our 
results, a larger study sample, with similar gender 
proportions and including all types of emphysema 
distribution, will be needed. Finally, some interobserver 
Table 2. Distribution of pulmonary emphysema according to functional status and the respective functional severity.
Variable Emphysema 
distribution
Frequencya Adjusted ORb (95% 
CI)
p
n (%)
FEV1 < 65% of predicted
c
Type 1
Type 2
Type 3
Type 4
14 (45.2%)
13 (61.9%)
12 (85.7%)
15 (78.9%)
1 (reference)
1.69 (0.32-8.92)
5.79 (1.06-31.64)
6.92 (1.43-33.45)
0.045*
0.537
0.043*
0.016*
6MWD < 350 mc
Type 1
Type 2
Type 3
Type 4
1 (3.6%)
2 (9.5%)
3 (21.4%)
9 (52.9%)
1 (reference)
1.63 (0.31-8.70)
5.58 (1.01-30.84)
6.36 (1.26-32.18)
0.064
0.567
0.049*
0.025*
Hypoxemiad
Type 1
Type 2
Type 3
Type 4
3 (13.0%)
4 (20.0%)
6 (50.0%)
9 (52.9%)
1 (reference)
2.85 (0.24-33.89)
7.60 (0.67-86.19)
32.66 (3.26-326.84)
0.006*
0.408
0.102
0.003*
6MWD: six-minute walk distance; type 1: obvious upper-lung predominance; type 2: slight upper-lung 
predominance; type 3: equal upper- and lower-lung extent; type 4: slight lower-lung predominance. aCorresponds 
only to patients with the lowest functional status, as defined in the first column. bAdjusted for age and body mass 
index. cCut-off value for the assignment of at least 1 point on the Body mass index, airflow Obstruction, Dyspnea, 
and Exercise capacity (BODE) index. dDefined as a PaO2 < 60 mmHg with an FiO2 of 0.21. *p < 0.05.
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variability is predictable, as previously noticed.(18,33,34) 
Such disagreement can be seen primarily for patients 
with the least severe emphysema and with only 
partial upper or lower lung predominance. In fact, 
most discordant cases were related to classification 
differences between contiguous types. 
In the past, direct visual observation and 
subjective visual grading were considered to have 
similar precision as the computer-assisted methods 
of emphysema quantification on CT scans.(35-39) 
Although we have not provided a direct measure of 
emphysema severity, the purpose of this study was 
to present a qualitative (rather than quantitative), 
simple, affordable alternative method that could be 
widely used by clinicians to classify the heterogeneity 
of pulmonary emphysema. 
In summary, in this group of COPD patients with 
pulmonary emphysema, lower lung-dominant distribu-
tion, as assessed by a subjective score, was found to 
have a significant impact on physiologic parameters, 
including pulmonary function test results and exercise 
capacity, although not on the clinical presentation of 
the disease, as assessed by the mMRC dyspnea scale 
score and the number of exacerbations in the last year. 
Further studies are warranted in order to confirm the 
importance of our findings.
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